Research Use Policy
PEPTIDES BIO / MATERIAL RECORD
Semaglutide 10mg
Research-use peptide material record: pack format, specifications and COA/SDS request for qualified laboratory review.
RESEARCH USE ONLYRUO
Semaglutide 10mg
Important NoticeThis product is for use only in vitro research. It is strictly prohibited for human injection, clinical treatment, food addition or any animal experiments. Please read our terms and conditions carefully before placing an order.
Volume pricing
Configured totals update at each quantity threshold.
Configured total$25.37
Request COA / MSDS
Research record
Pending manual confirmationResearch overview
Semaglutide is a long‑acting glucagon‑like peptide‑1 (GLP‑1) analogue with 94% sequence homology to human GLP‑1. As a GLP‑1 receptor agonist, it mimics the actions of native GLP‑1 by promoting glucose‑dependent insulin secretion, inhibiting glucagon release, and delaying gastric emptying. It also acts on the central nervous system to reduce caloric intake through appetite suppression and increased satiety. Its structure incorporates a fatty acid side‑chain modification that extends its half‑life to approximately 7 days, enabling once‑weekly administration. Semaglutide has received FDA approval for the treatment of type 2 diabetes and obesity. In addition to lowering blood glucose and promoting weight loss, clinical studies have also demonstrated clear cardiovascular and renal protective effects.
Research reference
Product FAQ
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist that works by mimicking the natural GLP-1 hormone. Through specific molecular modifications (amino acid substitutions and the addition of a C18 fatty diacid side chain), its half-life is extended to approximately 160 hours, allowing for once-weekly dosing. It shares 94% structural similarity with endogenous human GLP-1.
What is the mechanism of action of Semaglutide?
Semaglutide works through multiple mechanisms by activating the GLP-1 receptor:
· Stimulates insulin secretion from pancreatic β-cells (lowers blood glucose)
· Suppresses glucagon release from pancreatic α-cells
· Slows gastric emptying and increases satiety
· Acts on the hypothalamus to suppress appetite
· Reduces energy intake, promoting weight loss
What are the main research areas for Semaglutide?
· Type 2 diabetes (lowering blood glucose and HbA1c)
· Obesity and weight management (long-term weight control)
· Cardiovascular risk reduction (26% relative risk reduction in MACE)
· Chronic kidney disease
· Metabolic dysfunction-associated steatohepatitis (MASH)
· Polycystic ovary syndrome (PCOS)
· Non-alcoholic fatty liver disease (NAFLD)
Data sheet
Manual confirmation- Material Type
- Single material
- Purity Identity
- ≥99% purity
- Molecular Weight
- 4113.58 g/mol
- Pack Size
- 10mg
- Molecular Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Amino Acid Sequence
- H-{Aib}-EGTFTSDVSSYLEGQAA-{C18 diacid-γ-Glu-(AEEA)₂-Lys}-EFIAWLVRGRG
- PubChem CID
- 56843331
- Storage conditions overview
- Storage typeLong-termTemperature-80°CDuration2-3 yearsNotesSealed, dark, minimal openingStorage typeStandardTemperature-20°CDuration1-2 yearsNotesSealed, dark, moisture-proofStorage typeShort-termTemperature4°CDuration1-2 weeksNotesTemporary storage, use promptlyStorage typeWorking SolutionTemperature4°CDuration1-7 daysNotesReconstituted, short-term, avoid freeze-thaw